Olema Pharmaceuticals
OLMA
156 hedge funds and large institutions have $415M invested in Olema Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 53 increasing their positions, 39 reducing their positions, and 9 closing their positions.
19,222% more call options, than puts
Call options by funds: $1.74M | Put options by funds: $9K
311% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 9
160% more capital inflows, than outflows
Capital inflows: $208M | Capital outflows: $79.9M
36% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 39
20% more funds holding
Funds holding: 130 → 156 (+26)
1.89% more ownership
Funds ownership: 102.42% → 104.31% (+1.9%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$74.6M |
| 2 |
Paradigm Biocapital Advisors
New York
|
+$18M |
| 3 |
Avoro Capital Advisors
New York
|
+$16.5M |
| 4 |
Millennium Management
New York
|
+$9M |
| 5 |
Morgan Stanley
New York
|
+$7.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
-$34.2M |
| 2 |
Great Point Partners
Greenwich,
Connecticut
|
-$11.9M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$7.57M |
| 4 |
Deep Track Capital
Greenwich,
Connecticut
|
-$5.56M |
| 5 |
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.22M |
OLMA Hedge Fund Activity: Q4 2024 in Review
156 of the 7,618 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q4 2024, worth a combined $415M — down 41% from $700M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new OLMA positions and 9 closed out — a net gain of 28 holders — while 53 added to existing stakes and 39 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $74.6M. The largest seller was BVF Inc, cutting an estimated $34.2M.
- 156 institutional investors held Olema Pharmaceuticals (OLMA) as of Q4 2024, up from 130 in Q3 2024.
- Funds reported $415M of Olema Pharmaceuticals stock for Q4 2024, down 41% quarter-over-quarter.
- 37 funds opened new Olema Pharmaceuticals positions in Q4 2024 and 9 closed out, a net change of +28 holders.
- The largest Olema Pharmaceuticals buyer in Q4 2024 was Bain Capital Life Sciences Investors, an estimated $74.6M added.
- The largest Olema Pharmaceuticals seller in Q4 2024 was BVF Inc, an estimated $34.2M sold.
Based on aggregated 13F filings for Q4 2024.